RTS,S is a first-generation subunit malaria vaccine that targets the P. falciparum circumsporozoite protein (CSP) and is approved for use in humans, but RTS,S shows lower than desired efficacy and durability [2]. This evidence concerns the gene DNAJC5 and malaria.